Medizinische Klinik III - Hämatologie / Onkologie
CONFIDHENCE
Ivosidenib in combination with azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany